MILAN, Dec 22 (APM) - Recordati has bought three Bayer consumer health products which are sold in France, Il Sole 24 Ore reported on Tuesday.
Transipeg and TransipegLib are macrogol-based laxatives used for the symptomatic constipation in adults while Colopeg is a large volume bowel cleanser indicated in preparation for endoscopic exploration, the paper explained.
In 2016, the products had sales of around 10 million euros in France. Andrea Recordati, the Italian group’s chief executive described the products as “well-known brands” in France and said they fit well with his company’s strategy to reinforce its product portfolio in this market. "We are progressively enhancing our presence in the area of gastroenterology,” Il Sole 24 Ore reported him as saying.
The deal has given another boost to Recordati’s share price. It rose nearly 2% to more than 37 euros, moving it closer to its 40 euros high recorded in November. Recordati’s share price has risen almost 40% in the last 12 months, the paper added.
Drugs' spending reforms will be introduced - health minister
Health minister Beatrice Lorenzin has given assurances reforms will be introduced to manage drugs spending more effectively, news agency Adnkronos reported on Thursday.
Speaking at the presentation of a healthcare report, she said territorial expenditure, which includes pharmacy-dispensed drugs, is under control, but hospital budgets are being overspent.
“It is partly because the ceiling (on hospital spending) is too low and partly because we need a new governance for the sector. We are working at it a piece at a time and we will get there in the end,” she was reported as saying.
Patients’ groups criticise Tuscany’s biosimilars policy for rheumatism
Patients’ group have criticised Tuscany over its policy of substituting biologicals used to treat rheumatism with biosimilars, according to Sunday’s La Repubblica.
Associazione Nazionale Malati Reumatici (ANMAR) and its regional counterpart ATMAR say the region has introduced a series of provisions which threaten the therapeutic continuity of treatments which have already been started with biologicals.
“In particular, the 960 resolution of 2017 has effectively established the equivalence and substitutability of the originator biological drug with the reference biosimilar,” the associations were reported as saying.
They acknowledged the usefulness of biosimilar products in keeping treatments sustainable for the national health service and stressed they support their use in previously untreated patients. “But we are strongly against the substitution of the originator with a biosimilar in patients who for years have been treated successfully with biological therapies,” the patients’ groups said.
MolMed’s cell therapy Zalmoxis fairly priced - CEO
MolMed’s cell therapy Zalmoxis, which is used to facilitate transplants for blood cancer patients with only partially compatible donors, was fairly priced, the company’s chief executive told MF in an interview published on Thursday.
Riccardo Palmisano said the reimbursement cost agreed will allow the health service to plan its spending on the treatment while providing the biotech with an adequate return.
The paper noted that Zalmoxis will be marketed in Europe by fellow Italian group Dompé. The licence and distribution agreement will see MolMed receive up to 43.5 million euros from its partner, of which up 12.5 million euros will be earned between 2017-2020.
Palmisano pointed out that the production costs of a cell therapy can be 20 times higher than for biotech drugs because they are individually made for each patient.
The Molmed CEO, who is also head of the biotech association Assobiotec, said Italy has a vibrant biotechnology sector but warned about insufficient funding, a lack of venture capital and poor technology transfer capabilities.
Payback subtracts one billion euros from pharma investments
Italy’s payback scheme subtracts around one billion euros from potential pharma investment, the head of the industry body Farmindustria told Il Sole 24 Ore in an interview published on Friday.
However, Massimo Scaccabarozzi said that, despite the problems caused by the system, Italy could pass Germany next year as Europe’s largest producer of pharmaceuticals.
He highlighted how expansion in the south of the country has been especially rapid. Southern regions have doubled their pharma exports in the last 10 years, he told the paper.
Scientific community must comunicate better on vaccines
The scientific community need to communicate more effectively on vaccines, GlaxoSmithKline Vaccines’ chief scientist told news agency Adnkronos in an interview published on Thursday.
“We are still in the last century and the world has moved on. We need to change the way we present information,” Rino Rappuoli said. He suggested that one of the main messages should be that vaccines do not work if they are not used. The benefits of vaccines in the past need to be demonstrated so that people understand how they can combat infectious diseases today, he added.